Racecadotril
As of the edition of 20 October 2026, Racecadotril is a small molecule: marketed, first approved in 1992 (FR); acts on MME.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2005
- Kind
- Small molecule
- Brand name
- Tiorfan
- First approved
- 10 July 1992 (FR)
- Approvals on record
- 3 in 3 regions
- Holder of the most recent approval
- LABORATÓRIOS BAGÓ DO BRASIL S/A; 3 holders in all
- Registered trials
- 11, 0 stopped early
- Disease areas
- Digestive system; Infections; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| MME | Neprilysin | P08473 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 1 | 1 | 0 |
| Phase 1 | 5 | 4 | 0 | 0 |
| Phase 2 | 2 | 1 | 1 | 0 |
| Phase 3 | 1 | 1 | 0 | 0 |
| All trials | 11 |